Rodman & Renshaw Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

Rodman & Renshaw assumed coverage on shares of Rani Therapeutics (NASDAQ:RANI) in a research report sent to investors on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

Several other equities analysts also recently commented on the company. HC Wainwright upped their target price on Rani Therapeutics from $12.00 to $13.00 and gave the company a buy rating in a research report on Tuesday, May 7th. Canaccord Genuity Group reduced their price target on Rani Therapeutics from $21.00 to $9.00 and set a buy rating on the stock in a research report on Wednesday, March 27th. Finally, BTIG Research increased their price target on Rani Therapeutics from $7.00 to $14.00 and gave the stock a buy rating in a research report on Thursday, May 9th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $12.29.

Rani Therapeutics Price Performance

Rani Therapeutics stock opened at $4.03 on Thursday. Rani Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.75. The stock’s 50 day moving average is $5.57 and its 200-day moving average is $4.10. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $203.19 million, a price-to-earnings ratio of -3.12 and a beta of 0.25.

Rani Therapeutics (NASDAQ:RANI) last posted its earnings results on Monday, May 6th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities research analysts expect that Rani Therapeutics will post -1.02 EPS for the current year.

Institutional Investors Weigh In On Rani Therapeutics

An institutional investor recently raised its position in Rani Therapeutics stock. Vanguard Group Inc. boosted its holdings in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 685,303 shares of the company’s stock after purchasing an additional 16,956 shares during the period. Vanguard Group Inc. owned about 1.37% of Rani Therapeutics worth $2,131,000 at the end of the most recent quarter. Institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.